[go: up one dir, main page]

ZA200803350B - Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose - Google Patents

Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose

Info

Publication number
ZA200803350B
ZA200803350B ZA200803350A ZA200803350A ZA200803350B ZA 200803350 B ZA200803350 B ZA 200803350B ZA 200803350 A ZA200803350 A ZA 200803350A ZA 200803350 A ZA200803350 A ZA 200803350A ZA 200803350 B ZA200803350 B ZA 200803350B
Authority
ZA
South Africa
Prior art keywords
mitochondria
organism
acting
carrying
pharmaceutical composition
Prior art date
Application number
ZA200803350A
Other languages
English (en)
Inventor
Skulachev Vladimir Petrovich
Original Assignee
Ltd Liability Company Mitotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltd Liability Company Mitotech filed Critical Ltd Liability Company Mitotech
Publication of ZA200803350B publication Critical patent/ZA200803350B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B11/00—Diaryl- or thriarylmethane dyes
    • C09B11/04—Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
    • C09B11/10—Amino derivatives of triarylmethanes
    • C09B11/24—Phthaleins containing amino groups ; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200803350A 2005-10-18 2008-04-15 Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose ZA200803350B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2005132217/15A RU2318500C2 (ru) 2005-10-18 2005-10-18 Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели

Publications (1)

Publication Number Publication Date
ZA200803350B true ZA200803350B (en) 2009-02-25

Family

ID=37962744

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803350A ZA200803350B (en) 2005-10-18 2008-04-15 Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose

Country Status (13)

Country Link
US (1) US9328130B2 (fr)
EP (1) EP1937277A1 (fr)
JP (1) JP2009511626A (fr)
KR (1) KR20080059228A (fr)
CN (1) CN101300014A (fr)
AU (1) AU2006302751A1 (fr)
BR (1) BRPI0617417A2 (fr)
CA (1) CA2626305A1 (fr)
IL (1) IL190951A0 (fr)
MX (1) MX2008004939A (fr)
RU (1) RU2318500C2 (fr)
WO (1) WO2007046729A1 (fr)
ZA (1) ZA200803350B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066680B1 (fr) * 2006-09-28 2012-08-08 Medical Research Council Donneurs d'oxyde nitrique de type thionitrite de triphénylphosphonium
US9045505B2 (en) 2006-09-28 2015-06-02 University Of Otago Nitric oxide donors
EP2119436A4 (fr) * 2006-10-20 2010-03-03 Ltd Liability Company Mitotech Compositions pharmaceutiques pour la prévention et le traitement de pathologies oculaires
US8557733B2 (en) 2006-10-20 2013-10-15 Mitotech S.A. Composition for regenerating and stimulating growth of plants and for adapting plants to different stress factors
WO2008094061A1 (fr) 2007-01-29 2008-08-07 Limited Liability Company 'mitotechnology' Compositions pharmaceutiques et cosmétiques servant à accélérer le processus de cicatrisation de plaies et autres lésions superficielles
US8349902B2 (en) 2007-01-29 2013-01-08 Mitotech Sa Pharmaceutical compositions useful for preventing and treating oncological diseases
WO2008127138A1 (fr) 2007-04-11 2008-10-23 Limited Liability Company 'mitotechnology' Composition visant à ralentir le vieillissement et à allonger la durée de vie de l'organisme et utilisation de cette composition
WO2009005386A1 (fr) * 2007-06-29 2009-01-08 Limited Liability Company 'mitotechnology' Utilisation de compositions à adressage mitochondrial dans la prévention et le traitement de maldies cardio-vasculaires
KR101642157B1 (ko) * 2008-03-14 2016-07-22 스티븐 존 랄프 미토콘드리아로 전달되는 항암 화합물
CN102046178B (zh) * 2008-04-01 2013-05-08 安蒂博汀医药公司 用于皮肤护理的组合物和方法
CA2740773A1 (fr) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Traitement d'affections liees au stress oxydatif, notamment de la nephropathie aux produits de contraste, des radiolesions et des perturbations de la fonction des globules rouges
US9308214B2 (en) 2008-11-12 2016-04-12 Mitotech S.A. Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations
JP5659388B2 (ja) * 2009-06-10 2015-01-28 マイトテック ソシエテ アノニム 医学及び獣医眼科の使用のための医薬組成物
EP2500336A1 (fr) 2009-11-13 2012-09-19 Obschestvo S Ogranichennoi Otvetstvennostyu "Mitotekh" Substances pharmaceutiques à base d'antioxydants adressés à des mitochondries
EP2586776A4 (fr) * 2010-06-24 2014-02-19 Ltd Liability Company Mitotech Isolateurs mitochondriaux cationiques mous
RU2527519C2 (ru) * 2010-06-24 2014-09-10 Общество С Ограниченной Ответственностью "Митотех" Мягкие катионные митохондриальные разобщители
US20130288985A1 (en) * 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
SG187744A1 (en) * 2010-08-06 2013-03-28 Edison Pharmaceuticals Inc Treatment of mitochondrial diseases with naphthoquinones
WO2012110435A1 (fr) * 2011-02-14 2012-08-23 Basf Se Additifs pour procédé biologique
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
AU2012261854B2 (en) 2011-06-03 2017-11-16 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
BR112014002663A2 (pt) * 2011-08-04 2020-10-27 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food método para fornecer um ácido nucleico para uma organela não nuclear em uma célula, método para produzir uma célula vegetal geneticamente modificada, célula vegetal geneticamente modificada, método para produzir uma planta geneticamente modificada, planta geneticamente modificada, método para produzir uma célula animal geneticamente modificada, nanocarreador direcionado a mitocôndria e nanocarreador direcionado a cloroplasto
EP2758048B1 (fr) 2011-09-22 2021-05-19 Mitotech SA Antioxydants ciblant les mitochondries utilisables en vue du traitement des troubles cérébraux liés à l'âge
GB201117095D0 (en) 2011-09-30 2011-11-16 Univ Exeter The Novel hydrogen sulfide releasing compounds
EP2671574A1 (fr) 2012-06-04 2013-12-11 VitaK B.V. Utilisation de la vitamine K pour réduire la défaillance d'allogreffon et mortalité de patient après une transplantation d'organe
JP2015533794A (ja) 2012-09-07 2015-11-26 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス障害を処置するためのベンゾキノン誘導体
KR101490580B1 (ko) * 2013-02-15 2015-02-05 경북대학교 산학협력단 미토콘드리아 타겟팅용 펩타이드
WO2015063553A2 (fr) * 2013-04-11 2015-05-07 Mitotech S.A. Toluquinones et timoquinones à ciblage mitochondrial
WO2015162494A2 (fr) * 2014-02-25 2015-10-29 Mitotech, S.A. Compositions cosmétiques d'antioxydants à cible mitochondriale
EP3148528A1 (fr) 2014-06-02 2017-04-05 University of Exeter Associations d'un photosensibilisateur avec un donneur de sulfure d'hydrogène, un inhibiteur de la thiorédoxine ou un nitroxyde pour une utilisation en thérapie photodynamique
US20180185276A1 (en) * 2015-03-26 2018-07-05 Mitotech S.A. Contact lenses carrying mitochonrially-targeted antioxidants
CN107847588B (zh) * 2015-05-20 2021-12-28 免疫功坊股份有限公司 具有靶向部分及效应部分的分子构建体及其应用
RU2637279C2 (ru) * 2015-12-25 2017-12-01 Сергей Петрович Кречетов Способ фотодинамической терапии
CN105506053B (zh) * 2015-12-30 2018-06-19 北京农学院 一种草莓果肉细胞凋亡的检测方法
EP3330274A1 (fr) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Composés de traitement de troubles liés à la sénescence
US20210246144A1 (en) 2017-06-26 2021-08-12 Mitotech S.A. A set of mitochondria-targeted compounds
RU2020120686A (ru) * 2017-11-24 2021-12-24 Лунелла Байотек, Инк. Соединения производных трифенилфосфония для эрадикации раковых стволовых клеток
JP7447384B2 (ja) * 2018-06-21 2024-03-12 オスロ ウニヴェルスィテーツスィーケフース ハーエフ 方法
CN109232216A (zh) * 2018-11-11 2019-01-18 苏州怡彼得生物技术有限公司 一种线粒体靶向抗氧化剂skq1二季膦盐衍生物的合成方法
CN109232219A (zh) * 2018-11-11 2019-01-18 苏州怡彼得生物技术有限公司 一种线粒体靶向抗氧化剂skq1中间体2,3-二甲基-对苯醌的合成方法
CN113939342A (zh) * 2019-01-25 2022-01-14 Mti生物技术公司 连接三苯基膦鎓的水杨胺衍生物
WO2021119330A1 (fr) * 2019-12-10 2021-06-17 Maxim Skulachev Matrices polymères pour différentes compositions d'antioxydants à ciblage mitochondrial
CN110872220B (zh) * 2019-12-19 2022-04-26 苏州怡彼得生物技术有限公司 一种靶向抗氧化剂skq1中间体2,3-二溴-5,6-二甲基-对苯醌的合成方法
CN111117379A (zh) * 2020-01-13 2020-05-08 广州铭汇建设工程有限公司 管道防锈涂料
EP4125867A1 (fr) * 2020-04-03 2023-02-08 Mitotech S.A. Utilisation d'antioxydants ciblant les mitochondries pour traiter des états inflammatoires graves
EP4210695A4 (fr) 2020-09-09 2025-04-16 Social Profit Network Procédés et compositions pour l'administration de biotine à des mitochondries
CN112341493B (zh) * 2020-10-21 2023-08-15 重庆医药高等专科学校附属第一医院(重庆市职业病防治院重庆市第六人民医院重庆市中毒控制中心) 一种基于三苯基膦修饰的线粒体靶向褪黑素及其制备方法和应用
CN113480528B (zh) * 2021-08-16 2023-05-30 四川大学华西医院 一种专一靶向线粒体且高效产生单线态氧的咪唑类光敏剂及其制备方法
EP4493710A1 (fr) * 2022-04-06 2025-01-22 Kashiv Biosciences, LLC Procédé de culture cellulaire amélioré pour la production de protéine
CN116854664A (zh) * 2023-07-06 2023-10-10 湖北科技学院 具有荧光可视功能的线粒体靶向抗氧化剂及其制备方法
US12077553B1 (en) * 2023-11-09 2024-09-03 Mitotech Ltd Crystalline form of antioxidant compound
WO2025099491A1 (fr) 2023-11-09 2025-05-15 Mitotech Ltd Formes cristallines de composé antioxydant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
ATE296305T1 (de) * 1997-11-25 2005-06-15 Antipodean Biotechnology Ltd Antioxidantien mit spezifischer wirkung auf mitochondrien
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
CA2354743A1 (fr) * 2001-08-07 2003-02-07 University Of Otago Antioxydants cibles par des mitochondries
CA2397684A1 (fr) * 2002-08-12 2004-02-12 Michael P. Murphy Antioxydants cibles par des mitochondries
RU2280448C2 (ru) * 2002-11-10 2006-07-27 Институт биофизики клетки РАН Композиция с антиоксидантными свойствами и способ лечения болезней млекопитающих
EP1664069B8 (fr) * 2003-08-22 2015-07-01 Antipodean Pharmaceuticals, Inc. Derives de la mitoquinone utilises en tant qu'antioxydants cibles de maniere mitochondriale

Also Published As

Publication number Publication date
WO2007046729A1 (fr) 2007-04-26
AU2006302751A1 (en) 2007-04-26
US20080176929A1 (en) 2008-07-24
RU2005132217A (ru) 2007-04-27
RU2318500C2 (ru) 2008-03-10
EP1937277A1 (fr) 2008-07-02
MX2008004939A (es) 2008-09-12
CN101300014A (zh) 2008-11-05
JP2009511626A (ja) 2009-03-19
US9328130B2 (en) 2016-05-03
BRPI0617417A2 (pt) 2011-07-26
KR20080059228A (ko) 2008-06-26
IL190951A0 (en) 2009-09-22
CA2626305A1 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
ZA200803350B (en) Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
TWI365866B (en) Amide derivatives, process for preparation thereof and use thereof as insecticide
ZA200711040B (en) Method and composition for transdermal drug delivery
IL225207A (en) A derivative of multi-ring carbamoylpyridone, its pharmaceutical composition, its use and its preparation
IL185390A (en) A solid dosage form
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
IL185517A0 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
ZA200903160B (en) Sulfonyl-Phenyl-2H-[1,2,4]Oxodiazol-5-one Derivatives, Processes for their preparation and their use as pharmaceuticals
WO2007070052A3 (fr) Compositions pharmaceutiques et méthodes destinées à traiter ou prévenir une maladie associée à l'oxalate
IL218840A (en) Nitro-cyclic compounds, their pharmaceutical preparations and their uses
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
ZA200700397B (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
EP1972251A4 (fr) Contenant de type capsule et procédé d'administration l'utilisant
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
EP2215070A4 (fr) Nouveaux dérivés de 1,3-dihydro-5-isobenzofurancarbonitrile et composition pharmaceutiques les renfermant pour le traitement de l'éjaculation précoce
DE602007005601D1 (de) Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
EP2163244A4 (fr) Agent, composition pharmaceutique, ingrédient actif de cette composition pharmaceutique et méthode de traitement de la dépendance à l'alcool éthylique et/ou aux drogues servant à traiter les complications psychosomatiques et neurologiques de patients alcooliques et/ou toxicomanes
EP1896038A4 (fr) Methode et composition pour l'administration transdermique d'un medicament
ZA200809206B (en) Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled by precipitation and pharmaceutical formulations containing same
GB0809228D0 (en) Compounds inducing differentiation of myoblasts or muscle f bers into neuron cells,pharmaceutical composition including said compounds.